US 11,884,750 B2
Cationic cell penetrating peptides and the use thereof
Chang-Kyu Oh, Seoul (KR); Jae-Ho Lee, Gyeonggi-do (KR); Soon-Ik Park, Gyeonggi-do (KR); Jeong-Ho Park, Gyeonggi-do (KR); Won-Jin Park, Seoul (KR); and Yun-Chu Cho, Seoul (KR)
Assigned to CELLTROY CO., LTD., Seoul (KR)
Filed by CELLTROY CO., LTD., Seoul (KR)
Filed on Jul. 22, 2022, as Appl. No. 17/814,363.
Claims priority of provisional application 63/230,929, filed on Aug. 9, 2021.
Prior Publication US 2023/0053924 A1, Feb. 23, 2023
Int. Cl. C07K 7/08 (2006.01); A61K 47/64 (2017.01)
CPC C07K 7/08 (2013.01) [A61K 47/64 (2017.08); C07K 2319/10 (2013.01); C07K 2319/60 (2013.01)] 15 Claims
 
1. A method of delivering a biologically active molecule into a subject or cells, comprising:
(S1) preparing a cell penetrating peptide;
(S2) binding the biologically active molecule to the cell penetrating peptide to prepare a complex comprising the cell penetrating peptide and the biologically active molecule; and
(S3) administering the complex into a subject or cells in need thereof,
wherein the cell penetrating peptide consists of an amino acid sequence represented by General Formula below:
R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14,
wherein in General Formula, R14 is arginine (R), proline (P), lysine (K), or isoleucine (I);
at least one of R1 to R14 is proline (P);
when arginine (R) is assigned 1 point and lysine (K) is assigned 0.5 points
among R1 to R14, the sum of the peptide is 6.5 points or more;
the peptide includes one or more amino acids selected from the group consisting of valine (V), leucine (L), and isoleucine (I); and
wherein the cell penetrating peptide consists of any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 53.